top of page
Supported projects
NAYA Therapeutics
Clinical-stage biotech developing two next-generation modalities—astate-211 radiopharmaceuticals and NK cell-engaging bifunctional antibodies—for hepatocellular carcinoma and multiple myeloma.
PSCC's entrance
December 2025
Localization
USA - Florida
Modality
Targeted therapy
Development status
Biotech - Phase 1/1b
Award(s)
bottom of page